Year: 2019
Type: article
Study design: Observational Study
Abstract: Objective: To analyze the current treatment for low-risk prostate cancer (LRPC) in China.Methods: A national questionnaire survey titled "A survey of current treatment of LRPC" was designed and released nationally through the network from July 16 to August 3, 2017.Results: A total of 1,116 valid questionnaires were recovered.The percentages of preferred treatment by active surveillance (AS) or radical prostatectomy (RP) were 29.21% and 45.61%, respectively.A correspondence analysis showed that the physician in charge was more inclined to choose AS than RP.Respondents from different institution types, hospitals with different annual numbers of newly admitted patients with prostate cancer, and with different familiarity with the LRPC definition presented a significant difference in the preferred treatments (p < 0.05).Urologists chose AS or not for the following reasons: tumor progression (52.51%), potential medical disputes (42.56%) (i.e., medical disputes from patients or their relatives when urologists choose AS to treat patients with LRPC and the patient has a poor outcome), fear of cancer (41.94%), and surgical risk (39.07%).These reasons were ubiquitous, and there was no significant difference among urologists for these concerns (p > 0.05).Personal skills, surgical risk, and tumor progression were the most common factors that influenced whether AS or RP was preferred (p < 0.05).Concern about the medical disputes brought about by AS was a key factor for not choosing AS (p < 0.05).Conclusions: LRPC is still dominated by RP in China, followed by AS.Personal skills, surgical risk, and concern about tumor progression were the common factors influencing whether AS or RP was preferred.In addition, medical disputes brought by AS are another key factor for not choosing AS.There will be more Chinese data in the future to guide treatment of LRPC.
Source: Journal of Cancer
DOI: 10.7150/jca.29595
Authors: Yongbao Wei, Longfei Liu, Xin Li, Wei Song, Dewen Zhong, Xiande Cao, Daozhang Yuan, Shaoxiong Ming, Peng Zhang, Yanlin Wen, Jiu Jing Group12
Institutions: Fujian Medical University, Fujian Provincial Hospital, Central South University, Xiangya Hospital Central South University, Hunan Provincial People's Hospital, First Affiliated Hospital of Fujian Medical University, Affiliated Hospital of Jining Medical University, Guangzhou Medical University Cancer Hospital, Guangzhou Medical University, Second Military Medical University, Changhai Hospital, Wuhan University, Zhongnan Hospital of Wuhan University, Nanchong Central Hospital
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $1,337
OpenAlex ID: W2988916171